Canada: Life Sciences, Biotechnology & Nanotechnology

Subscribe
Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.
Article
Teva And Samsung Bioepis Add Up To Six Biosimilar Candidates To Partnership
Teva Pharmaceutical Industries and Samsung Bioepis have expanded their biosimilar partnership to include up to six new biosimilar candidates. Two confirmed candidates are SB41, referencing AstraZeneca's FASENRA (benralizumab) for eosinophilic asthma, and SB44, referencing Novartis's ILARIS (canakinumab) for systemic juvenile idiopathic arthritis and other inflammatory conditions.
Canada Finance
GP
Goodwin Procter LLP
Article
Patents In Canada: A Practical Guide For Foreign Businesses
Canadian patent law contains distinct procedural and substantive requirements that can significantly affect claim scope, prosecution costs, patent term, and enforceability for foreign companies. Understanding these differences—from software patentability standards to patent term adjustment opportunities—is essential for developing an effective North American IP strategy that maximizes protection while controlling costs.
Canada IP
MT
Miller Thomson LLP
Article
Life Sciences-Health Canada Takes Action Against Unauthorized Peptide Sales
On July 29, 2026, Health Canada announced that it had obtained a permanent injunction against a Québec-based company in connection with the sale of unauthorized injectable peptides in Canada. The announcement reflects Health Canada’s continued focus on peptide products and serves as a reminder that injectable peptides intended for human use are regulated as prescription drugs and are subject to Canada's drug regulatory framework.
Canada Healthcare
F
Fasken
Article
Pharmaceutical And Life Sciences Sector Federal Task Force Releases Final Report
On July 24, 2026, Health Canada published the Final Report of the Pharmaceutical and Life Sciences Sector Task Force to the Ministers of Health and Industry. The Task Force was launched in March 2026 as a joint federal initiative of Health Canada and Innovation, Science and Economic Development Canada. The Task Force’s mandate was to support reliable and sustainable access to pharmaceutical products in Canada and identify made-in-Canada solutions that drive innovation, competitiveness and long-term growth in the life sciences sector.
Canada Healthcare
F
Fasken
Article
Santé Canada Renforce Le Cadre De Gestion Des Pénuries De Médicaments Et D’instruments Médicaux
Le 17 juin 2026, Santé Canada a publié le Règlement modifiant certains règlements pris en vertu de la Loi sur les aliments et drogues (pénuries et cessation de la vente de drogues et d’instruments médicaux) (le « Règlement modificatif »), qui apporte des modifications au Règlement sur les aliments et drogues (RAD) et au Règlement sur les instruments médicaux (RIM).
Canada Healthcare
FF
Fasken (French)
Article
Cour suprême du Canada : les méthodes de traitement médical demeurent non brevetables, mais la validité du brevet de Janssen sur un schéma posologique de palipéridone est confirmée
La Cour suprême du Canada a rendu sa décision dans l'affaire Pharmascience Inc. c. Janssen Inc., 2026 CSC 26, concernant la brevetabilité des méthodes de traitement médical. La décision clarifie l'approche permettant de déterminer si une revendication constitue une méthode de traitement médical non brevetable, tout en confirmant la validité du brevet de Janssen sur un schéma posologique de palipéridone pour le traitement de la schizophrénie.
Canada IP
SB
Smart & Biggar
Article
Supreme Court Of Canada: Methods Of Medical Treatment Unpatentable, Validity Of Janssen’s Paliperidone Dosing Regimen Patent Upheld
The Supreme Court of Canada has ruled on the patentability of methods of medical treatment in Canada, affirming that such methods remain unpatentable while upholding the validity of Janssen's patent for a paliperidone palmitate dosing regimen. The decision provides crucial guidance on determining whether pharmaceutical claims constitute unpatentable medical treatment methods, focusing on the role of professional medical skill and judgment in practicing the claimed invention.
Canada IP
SB
Smart & Biggar
Article
Medical Devices Updates: Mandatory Use Of The Regulatory Enrolment Process For Medical Devices And Updated Guidance Documents Related To The Regulatory Enrolment Process
Health Canada released a notice to industry on April 24, 2026, outlining that manufacturers must use the Regulatory Enrolment Process (REP) and Common Electronic Submission Gateway (CESG) for medical device transactions as of April 1, 2026. As we previously reported, manufacturers of medical devices could voluntarily use the REP and CESG for medical device regulatory transactions as of July 2024.
Canada Healthcare
SB
Smart & Biggar
See more

Latest Videos

See more